










































The importance of clinician, patient & researcher collaborations
in Alport Syndrome
Citation for published version:
Rheault, MN, Savige, J, Randles, MJ, Weinstock, A, Stepney, M, Turner, N, Parziale, G & Gross, O 2019,
'The importance of clinician, patient & researcher collaborations in Alport Syndrome', Pediatric Nephrology.
https://doi.org/10.1007/s00467-019-04241-7
Digital Object Identifier (DOI):
10.1007/s00467-019-04241-7
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:




This article is distributed under the terms of the Creative
Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and
the source, provide a link to the
Creative Commons license, and indicate if changes were made.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
REVIEW
The importance of clinician, patient and researcher collaborations
in Alport syndrome
Michelle N. Rheault1 & Judith Savige2 & Michael J. Randles3 & André Weinstock4 & Melissa Stepney5 & A Neil Turner6 &
Gina Parziale4 & Oliver Gross7 & Frances A Flinter8 & Jeffrey H Miner9 & Sharon Lagas4 & Susie Gear10 &
Rachel Lennon3,11
Received: 24 February 2019 /Accepted: 15 March 2019
# The Author(s) 2019
Abstract
Alport syndrome is caused by mutations in the genes COL4A3, COL4A4 or COL4A5 and is characterised by progressive
glomerular disease, sensorineural hearing loss and ocular defects. Occurring in less than 1:5000, Alport syndrome is a rare
genetic disorder but still accounts for > 1% of the prevalent population receiving renal replacement therapy. There is also
increasing awareness about the risk of chronic kidney disease in individuals with heterozygous mutations in Alport syndrome
genes. The mainstay of current therapy is the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers,
yet potential new therapies are now entering clinical trials. The 2017 International Workshop on Alport Syndrome in Glasgow
was a pre-conference workshop ahead of the 50th anniversary meeting of the European Society for Pediatric Nephrology. It
focussed on updates in clinical practice, genetics and basic science and also incorporated patient perspectives. More than 80
international experts including clinicians, geneticists, researchers from academia and industry, and patient representatives took
part in panel discussions and breakout groups. This report summarises the workshop proceedings and the relevant contemporary
literature. It highlights the unique clinician, patient and researcher collaborations achieved by regular engagement between the
groups.
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Introduction
The 2017 International Workshop on Alport syndrome took
place in Glasgow and was formally designated as a pre-
conference meeting prior to the 50th anniversary meeting of
the European Society for Paediatric Nephrology (ESPN).
Following on from the previous highly successful workshops
in Oxford (2014) [1] and Göttingen (2015) [2], the meeting
brought together patients, researchers, clinicians and industry
participants from across the world. This review of the work-
shop proceedings and the contemporary literature highlights
the key updates in the following dominant themes that were
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covered in depth during the 3-day workshop: clinical science
and registries, genetics, basic science and the patient
perspective.
Clinical science and registries
A large portion of the workshopwas focussed on the clinical care
of patients with Alport syndrome including care at specific crit-
ical junctions such as diagnosis, transition to adult care and preg-
nancy (Fig. 1). Dr. Rachel Lennon reviewed the diagnostic eval-
uation of children with persistent haematuria including the im-
portance of obtaining a thorough family history. She also
discussed the importance of recognising the diversity of Alport
syndrome phenotypes and the role of genetic testing in diagnosis
to avoid the need for an invasive kidney biopsy. Individuals
presenting with early severe disease may have mutations in ad-
ditional genes affecting the glomerulus such asMYO1E [3]. Dr.
Lennon also reviewed the increasingly recognised phenotype of
nephrotic syndrome with focal segmental glomerulosclerosis on
kidney biopsy caused bymutations in type IV collagen genes [4].
Once a diagnosis of Alport syndrome is made, the next step is
determining a plan for follow-up and treatment. These topics
were reviewed by Drs. Clifford Kashtan and Oliver Gross.
Screening for non-renal manifestations of Alport syndrome is
important. Audiology evaluations are recommended once males
with X-linked Alport syndrome (XLAS) or males and females
with autosomal recessive Alport syndrome (ARAS) are 5–
6 years of age. Anyone with type IV collagen mutations and
overt proteinuria or clinical concern for hearing loss should have
formal audiology evaluations. Ophthalmologic manifestations of
Alport syndrome generally develop after adolescence, and
screening for males with XLAS or males and females with
ARAS should begin at age 15–16 years or sooner if symptom-
atic. Recommendations for the treatment of Alport syndrome
were published in 2013, and these remain the standard of care
[5]. Based on retrospective registry data, renin-angiotensin aldo-
sterone system (RAAS) blockade is recommended at the onset of
proteinuria regardless of genotype. For individuals with severe
mutations or family history of early (age < 30 years) end-stage
kidney disease (ESKD), then treatment may be considered when
patients are persistently microalbuminuric. Dr. Gross’s phase III
randomised placebo controlled study of ramipril treatment in
children at very early stages of Alport syndrome (isolated
haematuria or microalbuminuria) remains ongoing and is expect-
ed to report after 2019 [6]. The results of this trial will help to
determine if RAAS inhibition should be recommended at even
earlier ages to slow the progression of chronic kidney disease.
Alport syndrome is often diagnosed in childhood, necessi-
tating the transition of care from a paediatric to adult nephrol-
ogist. Drs. Arvind Nagra and Neil Turner reviewed the suc-
cessful ‘Ready Steady Go’ transition program in the UK [7].
Fig. 1 Clinical care in Alport syndrome. The presentations covered patient registries, precision medicine, genetic screening and clinical trials
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This program of educational materials and readiness assess-
ments provides a formal way to ensure smooth transition of
children with kidney disease, including children with Alport
syndrome. Pregnancy is also an important time of life for
women with Alport syndrome; however, little is known about
outcomes for women with this disorder [8]. Dr. Matt Hall
reviewed outcomes for women with chronic kidney disease
at the time of pregnancy and discussed improvements in both
maternal and foetal outcomes over the past several decades
[9]. Importantly, he reviewed the risks of RAAS inhibition in
pregnancy as these are commonly utilised drugs in this popu-
lation and known to be teratogenic.
Despite widespread use of RAAS inhibition, patients with
Alport syndrome are still at risk for progression to ESKD,
highlighting the need for clinical trials of novel agents in this
population. Prior to initiation of clinical trials, a detailed un-
derstanding of the natural history and clinical and biomarker
risk factors for progression is necessary. A number of Alport
syndrome registries are established around the world and pro-
vide valuable natural history information. In addition, an in-
ternational natural history study of patients with Alport syn-
drome recently completed follow-up (ATHENA study
NCT02136862). At the clinical science breakout session, the
group reviewed the current status of each of the registries and
agreed to further discussion of a recommended common
dataset of information to guide new registry formation and
facilitate data sharing between registries. In addition, some
of the preliminary data from the ATHENA study was
reviewed and publication of results is expected in 2019. The
first clinical trial specifically in patients with Alport syndrome
started enrolling in 2017. This randomised, placebo-
controlled trial of the NF-κB inhibitor bardoxolone
(NCT03019185) is a landmark for the Alport research and
patient communities, and additional clinical trials are in vari-
ous stages of planning.
The future of Alport syndrome treatment is bright. Dr.
Daniel Gale reviewed the complex pathway of bringing a
new drug to market including phase 1, 2 and 3 clinical trials;
approval and marketing; and cost considerations. Specific
challenges for clinical trials in Alport syndrome include the
rare nature of the disease for successful recruiting into clin-
ical trials as well as potential high costs of therapy for pa-
tients if a drug is approved. Dr. Michelle Rheault reviewed
the importance of understanding the molecular pathways of
glomerular filtration barrier dysfunction in Alport syn-
drome including molecular and cellular changes in
podocytes and endothelial cells in response to mechanical
strain, as well as changes in composition of the glomerular
basement membrane (GBM) [10]. A number of agents are in
clinical development for non-Alport syndrome indications
that may be appropriate for use in this population based on
molecular targets of drug action. For example, endothelin-1
appears to be upregulated in Alport glomeruli in response to
mechanical strain and may be targeted by endothelin-1 re-
ceptor antagonists currently in development [11].
Genetics
The presentations on genetics and diagnosis of Alport syn-
drome demonstrated that our understanding of the value of
genetic testing in Alport syndrome has increased greatly over
the past 18 months (Fig. 2). In many centres, gene testing has
replaced renal biopsy for the diagnosis of Alport syndrome
[12]. Identifying the underlying mutation(s) indicates the
mode of inheritance, enabling the targeted genetic testing of
other family members who may be at risk, as well as some-
times predicting the age at onset of ESKD [13]. Furthermore,
some therapies may be specifically targeted at people with
missense or nonsense variants in the future.
In addition, COL4A3, COL4A4 or COL4A5 mutations are
found in 10–30% of patients with focal and segmental
glomerulosclerosis (FSGS) [4, 14], and Dr. Moin Saleem re-
ported that some patients with features consistent with steroid-
resistant nephrotic syndrome had COL4A variants on screen-
ing with a 70-gene renal panel.
Genetic and non-genetic factors influence the prognosis to
a far greater extent than thought previously. Drs. Roser Torra
and Alessandra Renieri presented data suggesting that COL44
mutations result in a more severe phenotype than COL4A3
mutations. In their experience, up to one third of patients with
heterozygousCOL4A4mutations developed renal impairment
at an average age of 56 years. In addition, there is now evi-
dence for testing for coincidental mutations in NPHS2,MYH9
and ACTN4, which all influence proteinuria [3, 15, 16]. In Dr.
Constantinos Deltas’ experience, up to 16% of individuals
with a heterozygous COL4A3 or COL4A4 mutation develop
renal impairment and 41% have FSGS. The p.R229Q variant
in NPHS2 predisposes to increased proteinuria and renal fail-
ure, and the Rictor gene component of the mTORC2 pathway
may be a further modifier of renal function.
For men with XLAS, and men or women with ARAS, the
genetic results strongly predict outcome [17, 18], although the
clinical coursemay bemodified significantly by screening and
early ACE inhibitor treatment [19, 20]. The debate about an
appropriate nomenclature for individuals with a heterozygous
COL4A3 or COL4A4 mutation or a woman with a COL4A5
mutation continues [21]. For women with a heterozygous
COL4A5 mutation, or anyone with a heterozygous COL4A3
orCOL4A4 pathogenic variant, our ability to predict the future
is more constrained, but these individuals should all undergo
life-long renal surveillance [22]. Published data on the risk of
ESKD are skewed by ascertainment bias, with an over-
representation of people with ESKD in hospital-based series.
The risk of ESKD is probably lower in women with a
COL4A5mutation than historical data suggest, but still higher
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than in individuals with a pathogenic heterozygous COL4A3
or COL4A4 variant.
Some congress participants subscribed to the view that
anyone with a heterozygous COL4A3 or COL4A4 mutation
should be diagnosed with Alport syndrome, to ensure that the
significance of their diagnosis is appreciated and to ensure
aggressive management and long-term monitoring [21].
Others, while agreeing on the need for life-long follow-up,
do not classify people with a single mutation as having
Alport syndrome, because of their lesser risk of ESKD and
absence of extra-renal manifestations. If every person with a
heterozygous COL4A3 or COL4A4 mutation were labelled
with the diagnosis of Alport syndrome, its incidence would
increase from the current level of 1 in 5–10,000 to as high as 1
in 100 [23, 24], with ESKD being uncommon. At the meeting,
there was, however, unanimous agreement about the need for
long-term monitoring, screening of other family members and
a low threshold for prescribing ACE inhibitors to treat pro-
teinuria or hypertension. Clearly, more comprehensive
genotype/phenotype data are needed to enable an objective
calculation of the risk of renal impairment in heterozygous
carriers. Single mutations are significant susceptibility factors
for renal impairment in later life, but other factors, including
lifestyle attributes such as obesity, diabetes, exercise, untreat-
ed hypertension and proteinuria, are important too.
Pregnancy-associated hypertension represents a risk factor in
women with heterozygous COL4A5 mutations, and close
monitoring is required throughout each pregnancy.
Whole-exome and whole-genome studies are identifying
many more genetic variants in Alport genes, but this abun-
dance adds to the work of confirming pathogenicity. The
American College of Medical Genetics Guidelines for the
classification of variants are very clear [25], and their univer-
sal adoption, together with submission of variants to the
Leiden Open Variation Database (LOVD) or other databases,
will help us understand the significance of individual variants
better, especially heterozygous variants in the COL4A genes.
Basic science
As with previous Alport workshops, there were exceptional
speakers who delivered talks regarding fundamental research
relevant to Alport syndrome (Fig. 3). Dr. Billy Hudson, from
Vanderbilt Medical Centre, gave an impassioned talk where
he emphasised the critical importance of understanding the
basic molecular mechanisms governing the ‘molecular rope’
formed by the three type IV collagen alpha chains that, when
defective, cause Alport syndrome. His research group recently
investigated type IV collagen at the evolutionary dawn of
metazoan tissues by utilising Ctenophora. This is due to
Ctenophora being one of the earliest branching extant animal
Fig. 2 Diagnosis and genetics. The importance of education and raising awareness was discussed together with the classification of Alport syndrome.
Genomic sequencing projects such as 100,000 (100 k) genomes in the UK will help inform about the frequency of Alport gene mutations
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phyla. Their studies revealed that type IV collagen is present
in Ctenophora but absent in unicellular sister-groups, thus
suggesting that type IV collagen is one of the fundamental
architectural units for multicellular tissue genesis [26]. Dr.
Hudson stressed the key role of protein–protein interactions,
not only intra-type IV collagen interactions but also of the
interactions of type IV collagen with other basement mem-
brane (BM) components, including laminins and nidogens,
in addition to cell surface receptors such as integrins.
Dr. Wilhelm Kriz followed up Billy Hudson’s talk by first
presenting data on the mesangium as a ‘dumping ground’ for
defective and degraded glomerular BM (GBM) material.
Evidence from the 1970s suggests that the GBM is turned
over approximately every 65–100 days [27], and undoubtedly,
this turnover is essential for a normal functioning GBM. Dr.
Kriz demonstrated, using transmission electron microscopy
(TEM), in addition to staining for specific GBMmarkers, that
the mesangial matrix contains turned over GBM material.
Furthermore, he showed evidence that increased production
and defective degradation of GBM during diabetic nephropa-
thy (DN) contributes towards mesangial matrix expansion
[28]. He then drew parallels between DN and Alport syn-
drome by analysing Alport patient TEM samples. Dr. Kriz
hypothesised that the defective GBM component in Alport
syndrome is likely to be shunted to the mesangial
compartment in a mechanism similar to that seen in DN.
This process may have an important role in Alport syndrome,
leading to expansion of the mesangial matrix compartment
and eventual loss of glomerular function. Interestingly, Dr.
Kriz went on to explore the role of mechanical force within
glomeruli and the consequent impact on Alport pathology.
The glomerular capillary wall is exposed to high flow rates
causing sheer stress [29]. The GBM is known to create the
main wall tension during glomerular filtration; however, this
causes the GBM to expand, and at a critical point, the GBM
can no longer cope with the forces involved. Therefore, con-
traction of podocytes [30, 31] and mesangial cells [32] is
required to contribute to withstand the forces across the glo-
merular capillary wall. Dr. Kriz described how the location of
podocytes, attached to the outside of the GBM, leaves them
susceptible to detachment and loss from the glomerulus in the
urine. Moreover, podocytes located close to the hilum are
more susceptible to this process because of the high flow rates;
it is likely that podocytes that detach here cause a local in-
crease in force that prevents reattachment [29].
Dr. Oliver Gross presented work from his laboratory ex-
ploring the role of environmental modifiers of glomerular dis-
ease such as obesity, high calorie intake and high sodium, in
addition to treatment with angiotensin-converting enzyme in-
hibitors, the most common treatment for Alport patients
Fig. 3 Basic science. The presentation covered the different experimental systems in use to investigate the biology of type IV collagen and basement
membranes. There was a focus on the mechanisms of hearing loss in Alport syndrome
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(Fig. 4). Mouse models of both steroid-resistant nephrotic
syndrome and Alport syndrome are being used, and this ap-
proach has the potential to discover the efficacy of the stan-
dard treatment for Alport syndrome taking into account many
environmental factors.
Mouse models and human patient data are the most
frequently used in the Alport research community, which
has led to major discoveries in the past 30 years.
However, both higher throughput systems including
zebrafish, which have utility for high throughput screens
and high-resolution in vivo imaging, and larger mamma-
lian models of Alport syndrome are required to bridge the
gap in Alport research. Dr. Mary Nabity is studying a
canine model of XLAS. These animals have a lifespan
of around 1 year, and Dr. Nabity has analysed RNA-seq
samples collected at clinical milestones of glomerular dis-
ease development in these animals [33]. From this study,
Dr. Nabity has discovered new genes that are differential-
ly expressed between the slow and rapid progressing an-
imals with Alport syndrome, including lysyl oxidase
(LOX) transcripts. Further studies into the role of these
transcript changes may provide powerful insight into the
mechanisms leading to slow or rapidly progressing Alport
syndrome. Another key area of research pertinent to
Alport syndrome is regenerative medicine. In recent
years, there has been tremendous progress in the genera-
tion of protocols for the differentiation of stem cells into
renal progenitors and kidney organoids [34, 35]. Dr.
Laura Perin is seeking to apply regenerative medicine to
derive a treatment for Alport syndrome. She has developed
systems involving stem cells taken from amniotic fluid [36]
and has discovered a potential role for extracellular vesicles,
produced by stem cells, in modulating vascular endothelial
growth factor (VEGF) signalling in glomerular pathobiology.
Deeper understanding of this process may indeed lead to po-
tential drug targets in Alport syndrome.
Protocols for isolating and culturing podocytes from urine
have been employed in a number of studies [37], and although
known to be challenging, these approaches enable researchers
to gain insights into podocyte biology. Dr. Sergio Daga, from
The University of Siena, has been using this approach to iso-
late podocytes and subsequently use CRISPR gene editing
technology to study Alport syndrome. This area of research
has the potential to unlock further mechanistic insights in
Alport syndrome.
The therapeutic potential of anti-miR-21 for the treat-
ment of Alport syndrome was first investigated by Dr.
Jeremy Duffield and colleagues in 2015 with promising
results [38]. Dr. Tsubasa Yokota from Dr. Hirofumi Kai’s
laboratory has been building on some of these findings from
this study. STAT3 and IL6 were found to be increased in
mice with Alport syndrome before anti-miR-21 treatment;
the group, therefore, investigated the impact of STAT3 and
IL6 inhibitors in Alport mice. They found that STAT3 inhi-
bition reduced proteinuria, whereas IL6 inhibition had no
effect on this metric of glomerular function [39]. This is not
the only treatment that the group have tested in Alport mice;
bromide supplementation was also tried, as Billy Hudson
had shown bromide to be important for type IV collagen
network formation [40]. However, bromide supplementa-
tion exacerbated Alport pathology [41]. Dr. Kai’s research
group investigations into both the repurposing of licensed
drugs, including metformin, and novel therapies are of vital
importance for the Alport community.
Fig. 4 Factors that influence the
progression of Alport syndrome.
Treatments that have confirmed
or proposed effects on protecting
kidney function, cardiovascular
risk and hearing (top half in
green) and factors that are known
or thought to be deleterious








Despite renal pathologies being the focus of the Alport
workshop, there is a desperate need for more research into
the hearing impairment caused by Alport syndrome. Dr.
Dan Jagger, from University College London, delivered a
talk to provide some insights into the sensorineural hear-
ing loss found in individuals with Alport syndrome. It is
known that hearing loss occurs in Alport syndrome, but
there is no evidence for a disorder in balance, which may
be anticipated if there is progressive damage to the inner
ear. The structure thought to be most likely progressively
damaged in Alport patients is the basilar membrane of the
cochlea. The basilar membrane sits on a basement mem-
brane which is composed of type IV collagen a3a4a5.
Both inner and outer hair cells of the cochlea are exposed
to forces, which in turn are converted to electrical signals
interpreted by the brain as sound. Evidence suggests that
it is the outer hair cells that are damaged in Alport syn-
drome. The outer hair cells are the ‘amplifiers’ of the
signal generated by the inner hair cells, which is why a
‘base level’ of hearing that can be amplified with hearing
aids remains in individuals with Alport syndrome.
Although it is uncertain whether the hearing loss pheno-
type is present in all mouse models with Alport syndrome,
Dr. Jagger warned about the future of hearing research in
Alport mice, as it is well known that there is age-related
hearing loss in mice, which may confound studies. The
most obvious current advice to patients with Alport syn-
drome is to avoid exposure to mechanical damage, for
instance use of head phones.
Patient perspectives
Representatives from National Patient Organizations were in
attendance from Australia, China, France, Germany, Italy,
The Netherlands, Spain, the UK and the USA. In addition to
attending the main session, a pre-event meeting took place
with these groups to discuss how they could better collaborate
with each other to provide improved resources and support to
patients and encourage research. The creation of an
International Alport Organization was discussed to achieve
this and elements of this organization were captured by the
meeting illustrators. It was agreed that there are significant
challenges to the creation of such an organization. Amongst
these were:
& Dependence on volunteers for organization and resources.
& Significant differences in treatment resources and needs
between different countries.
& Differences in effective communication modes.
& Differences in cultural attitudes towards disease, privacy
and the physician–patient relationship
These challenges closely mirror those posed to creation
of an International Alport Patient Registry discussed in
past workshops. Susie Gear of Alport UK proposed a
series of potential logos for an International Alport
Organization (Fig. 3).
Recognising the importance of the patient perspective in
research and the development of potential therapies, patients
were asked to share their stories with the larger group (Fig. 5).
Andre Weinstock from the USA shared his experience as a
patient who had a transplant and continues to experience hear-
ing loss. This led to a discussion about the role of hearing loss
in Alport syndrome as an important quality of life concern.
Jessie Zhang, a mother of an Alport patient from China, spoke
about the need for patients to connect with each other as part
of a community to alleviate feelings of isolation, gain knowl-
edge and resources, and work together for advocacy. The
Alport Collective, a group of teenage patients from the UK,
shared videos they created to improve communication among
teens about Alport syndrome, and these are accessible on
YouTube : h t t p s : / /www.you tube . com/wa t ch?v=
Ps3rMpx7YZg, https://www.youtube.com/watch?v=
5gJEtmhcClU. Maria Jose, from Spain, spoke of the patient
advocacy organization’s efforts to unite their community.
While each journey was different, all conveyed the
importance of having a community to provide support and
resources.
In addition, patient groups play a critical role in re-
search and the development of potential therapies. These
groups are instrumental not only in recruiting patients for
research but also conveying the patient perspective to re-
searchers and industry. Gina Parziale, Executive Director
of the Alport Syndrome Foundation in the USA shared
their plans for an Externally Led Patient Development
Meeting. It took place in San Diego in October 2018
and brought together patients and their care-partners, rep-
resentatives from the US Food and Drug Administration
(FDA), pharmaceutical companies interested in develop-
ing drugs for the disease, and physicians—all to hear from
patients about Alport syndrome. In these meetings, the
patient’s experience is brought to the forefront for govern-
mental regulatory bodies, pharmaceutical companies and
academic researchers to understand.
The Healthtalk project on Alport syndrome
As a further expansion of the patient voice, the meet-
ing also heard about the Healthtalk project on Alport
syndrome. The importance of listening to patient expe-
riences is central to formulating health policy in the
UK (and many other countries) [42]. Research suggests
that hearing other people’s experiences, alongside
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factual information, engages people’s attention and in-
fluences and supports treatment decision making [43,
44].
From 2015 to 2017, a research project collaboration
between Alport UK and the University of Oxford led to
a freely accessible resource on Alport syndrome at the
website Healthtalk.org. Based on rigorous qualitative
research, Healthtalk provides a multi-media internet re-
source on the experiences, information and support
needs of people with different health issues. The site
already features 110 different conditions, had more than
6 million visitors in 2018 and is based on more than
4,000 in-depthnarrative interviews of peoples’ experi-
ences of health and illness. Health conditions on the
site include several major cancers,cardiovascular disease,
mental health, epilepsy, rheumatoid arthritis, pregnancy,
screening, sexual health and experiences of carers
ofpeople with dementia. The interviews are generated
and analysed by experienced social science researchers,
most of whom are based in the Health Experiences
Research Group within the University of Oxford’s
Nuffield Department of Primary Care Health Sciences
www.phc.ox.ac.uk/research/health-experiences. Dr.
Melissa Stepney (co-author) conducted the interviews
and analysis for the section on Alport Syndrome. The
Healthtalk sections have direct relevance for health and
social care professionals and students, schools, under-
graduate and post-graduate learning and teaching.
Further, the website section on Alport syndrome provides
an evidence base for patients and the public, learning and
teaching, policy makers, all who want to consult a balanced,
patient-led collection of experiences. Here, narrative inter-
views were conducted with 38 people with Alport syndrome,
including families and partners, and 3 interviews with
healthcare professionals with expertise on Alport syndrome.
The patient interviews offer in-depth knowledge and first-
hand experiences of what it is like to actually live with
Alport syndrome. On the site http://healthtalk.org/peoples-
experiences/long-term-conditions/alport-syndrome/overview,
there are around 27 topic summaries with 250 video clips
chosen to reflect issues important to participants, such as the
first signs and symptoms of Alport syndrome, getting a
diagnosis of Alport syndrome, medication, reproductive
choices, living as a female ‘carrier’ and the emotional side
of living with Alport syndrome. Although this study was
UK based, many of the overall experiences are similar
across the world—in practice, this means that when a person
with Alport syndrome looks at any of these summaries, they
should find that an experience or perspective akin to their own
is included, although this may not necessarily be reported by a
person of the same age, family situation or social class as
themselves. This baseline understanding of UK patients is
Fig. 5 Patient perspective. Four presentations from members of Alport syndrome patient organisations highlighted the importance of the patient voice
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critical in order to inform further projects and toolkits to better
support patients in the future, including improving communi-
cation, more effective and efficient clinical care, much needed
mental health support and the treatment of female ‘carriers’.
Summary
Overall, this review highlights the current and significant de-
velopments in Alport syndrome research from clinical and
basic science to genetics and qualitative research with pa-
tients. The collaboration between clinicians, patients and re-
searchers is key to accelerating the current research efforts in
order to deliver the unmet needs of patients living with Alport
syndrome.
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